DCM
EPZM

DAFNA Capital Management’s Epizyme, Inc EPZM Stock Holding History

DAFNA Capital Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-105,900
Closed -$1.64M – 95
2020
Q1 		$1.64M Buy
105,900
+37,900
+56% +$814K 0.69% 38
2019
Q4 		$1.67M Sell
68,000
-53,986
-44% -$801K 0.57% 41
2019
Q3 		$1.26M Sell
121,986
-51,550
-30% -$650K 0.47% 53
2019
Q2 		$2.18M Buy
+173,536
New +$2.23M 0.82% 35
2015
Q2 		– Sell
-20,000
Closed -$376K – 86
2015
Q1 		$376K Buy
+20,000
New +$413K 0.29% 52

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

DAFNA Capital Management's EPZM Position: Q2 2020 in Review

DAFNA Capital Management sold out of Epizyme, Inc (EPZM) in Q2 2020, closing a stake of 105,900 shares — an estimated $1.64M sold.

DAFNA Capital Management first reported a position in EPZM in Q1 2015 and held it in 5 quarters. The position peaked at $2.18M in Q2 2019. 160 funds tracked by Wall St. Rank hold EPZM as of Q2 2020.

  • DAFNA Capital Management reported no remaining Epizyme, Inc position as of Q2 2020 after selling out during the quarter.
  • DAFNA Capital Management sold 105,900 Epizyme, Inc shares in Q2 2020, an estimated $1.64M.
  • DAFNA Capital Management first reported a position in Epizyme, Inc in Q1 2015 and held it in 5 quarters.
  • DAFNA Capital Management's Epizyme, Inc position peaked at $2.18M in Q2 2019.
  • 160 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2020.

Based on DAFNA Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.